The present invention relates to a method for assessing a hematological
disease in a sample of a subject, said method comprising (a) determining in said sample at least five biomarkers selected from the
list consisting of GNLY, ZNF683, GZMH, FGFBP2, GZMB, NKG7, CCL5, HOPX, KLRD1, EFHD2, CD8A, CTSW, CST7, ITGB1, BHLHE40, LYAR, S100A4, GZMA, MXRA7, KLRK1, SH3BGRL3, ITGA4, FCRL6, TGFB1, CCL4, ZEB2, AOAH, AHNAK, S100A10, LGALS1, PRF1, ITGB2, CD52, TPST2, PRSS23, ANXA1, CYBA, C12orf75, LAIR2, MATK, S100A6, TNFAIP3, CLIC1, KLF6, C1orf21, SYNE2, HLA-DPB1, HLA- DPA1, DSTN, CD99, TAGLN2, PLEK, LINC02446, RPS26, RGCC, NFKBIA, FOS, PPP2R5C, CRIP1, AKAP13, ZFP36, and FLNA; and (B) thereby assessing said hematological
disease. The present invention further relates to methods, systems, kits and databases related thereto.